Cincinnati, OH and Redlands, CA - Schulman IRB, the industry-leading central IRB for customer service and technology, and iMedRIS Data Corporation, the fastest growing technology provider for optimizing research compliance and administration software, are pleased to announce their partnership to provide research organizations with integrated technology, consulting and IRB review services.
Rather than contracting with multiple disparate service providers, research organizations and institutions can now work with a single organization for IRB review services, research management technology, and good clinical practice (GCP) and human research protections (HRP) consulting services.
“This partnership offers unparalleled service integration for ultimate ease of use,” said Michael Woods, President and CEO at Schulman IRB. “Schulman is delighted to now be able to offer clients the industry’s most flexible and user friendly research management tools available.”
“iMedRIS and Schulman share the same high standards of customer service and support, and we are excited to share Schulman’s services with our clients,” said William Schroeder, CEO at iMedRIS. “This represents two of the research community’s most trusted partners coming together to provide an integrated service package of unprecedented opportunities.”
This integration reflects the first phase in iMedRIS’ and Schulman IRB’s partnership. The two organizations will continue to evaluate their service offerings to find additional ways that clients can benefit from the collaboration.
About iMedRIS
iMedRIS’ primary focus on client satisfaction and success has made the company a leader in research software solutions. Through iRIS, iMedRIS has been able to enhance its principles and foundation as the fastest growing small business within the industry to emerge as the preferred integrated Research Information Software provider. Through the iRIS system’s scalable configurations and enhanced process of improvement, the capability to process electronic submissions has empowered researchers to be more accurate and efficient. These established principles and focus on institutional requirements have enabled iMedRIS to maintain its mission and goals in order to provide the research community with state of the art software and enhance institutional research programs.
About Schulman IRB
Schulman IRB has been a leader in the protection of human research participants in the U.S., Puerto Rico and Canada since 1983. Schulman offers thorough, timely IRB review services – including dedicated review capabilities for all phases of research across all therapeutic areas – to clinical trial sponsors, CROs, investigators and institutions. Schulman also provides global consulting services through its Provision Research Compliance Services division, offering comprehensive solutions to maximize the protection of human subjects and improve overall quality standards for clinical studies and data integrity. Fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), Schulman has an unparalleled clean audit history with the Food and Drug Administration (FDA).
For more information, please visit http://www.sairb.com or follow @SchulmanIRB on Twitter or on LinkedIn.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.